Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
News|Articles|November 22, 2013
Aspirin at Bedtime vs. Aspirin in the Morning: Which Produces Greater Cardiovascular Benefits?
Author(s)Bridget Barry Thias
Although there appears to be no difference in blood pressure reduction in patients who take aspirin at bedtime compared to those who take it when they awake in the morning, bedtime aspirin may be associated with reduced morning platelet reactivity.
Advertisement
Advertisement
Aspirin is the most commonly used medication for cardiovascular disease prevention, with millions of patients using it every day. Although previous studies have indicated that patients with hypertension who take aspirin at bedtime experience slightly better blood pressure control compared to patients who take aspirin in the morning, similar comparison studies in patients with cardiovascular disease have not been performed.
Related to this article
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Advertisement
Advertisement